alexa The Influence of GSTA1 Polymorphism to the Response to

Lupus: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Short Communication

The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis Patients

Hong-Na Wang1, Xiao-Ye Zhu2, Ying Zhu2, Miao Zhao3, Yuan-Cheng Chen3, Jun Xue2*, Chuan-Ming Hao2, Yong Gu2 and Shan-Yan Lin2

1Department of Nephrology, Haihe Hospital,890 Jingu Road, Tianjin 300350, China

2Department of Nephrology, Huashan Hospital, Fudan University, 12 middle Wulumuqi Road, Shanghai 200040, China

3Institute of Antibiotics, Huashan Hospital, Fudan University, 12 middle Wulumuqi Road, Shanghai 200040, China

*Corresponding Author:
Xue J
Department of Nephrology, Huashan Hospital
Fudan University, 12 middle Wulumuqi Road
Shanghai 200040, China
Tel: 86-21-52887797
E-mail: [email protected]

Received date: March 23, 2016; Accepted date: April 25, 2016; Published date: April 29, 2016

Citation: Wang NH, Zhu XY, Zhu Y, Zhao M, Chen YC, et al. (2016) The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis Patients. Lupus Open Access 1:115. doi:10.4172/loa.1000115

Copyright: © 2016 Wang HN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Variations of clinical response of cyclophosphamide (CTX) treatment in lupus nephritis (LN) could still be recognized. LN patients with a GSTA1mutation (CT heterozygous) had a risk of none-response (P=0.005). Pharmacokinetics data indicated that patients with a GSTA1 heterozygous variant had a lower exposure to 4-OHCTX compared to wild-type patients (P=0.023). And clinical efficacy was significantly related to higher exposure to 4- OH-CTX (P=0.038). In conclusion, LN patients with GSTA1 heterozygousgenotypes had poor CTX treatment response due to less exposure to activated 4-OH-CTX.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords